Adjuvant Bevacizumab Does Not Increase Survival in High-Risk Melanoma

Share this content:
Adjuvant bevacizumab improves the long-term disease-free interval in melanoma, but OS is not significantly affected.
Adjuvant bevacizumab improves the long-term disease-free interval in melanoma, but OS is not significantly affected.
The following article features coverage from the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois. Click here to read more of Oncology Nurse Advisor's conference coverage. 

CHICAGO — Adjuvant bevacizumab does not improve overall survival of patients after resection of high-risk melanoma, according to study findings presented at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting.

The finding is from AVAST-M, a phase 3 trial evaluating single-agent bevacizumab (7.5 mg/kg IV 3 times weekly for 1 year) as adjuvant therapy after resection of AJCC stage IIB, IIC, and III cutaneous melanoma compared with standard observation.

“Adjuvant bevacizumab improves the long-term disease-free interval, but this did not translate into a significant improvement in distant-metastasis-free or overall survival,” lead investigator Philippa Corrie, PhD, of the Cambridge Cancer Trials Centre in Cambridge, United Kingdom, told meeting attendees.

Dr Corrie and her colleagues recruited 1343 patients and randomly assigned 671 to bevacizumab and 672 to observation. Patients had a median age of 56 years (range 18 to 88 years). In this group, 14% of patients were stage IIIA and 59% were stage IIIB/C.

After a median follow-up of 6 years, 505 patients (38%) died: 251 (37%) in the bevacizumab arm and 254 (38%) in the observation arm. A total of 699 patients (52%) experienced disease recurrence: 355 (50%) in the bevacizumab group and 369 (55%) in the observation arm.

The 5-year disease-free rate was 51% among bevacizumab recipients compared with 45% in the observation arm (HR 0.85; 95% CI, 0.74-0.99; P =.04). The 5-year overall survival rate was 64% in the bevacizumab group and 63% in the observation arm, a difference that was not statistically significant (HR 0.99; 95% CI, 0.84-1.18; P =.96).

In addition, at 5 years, the distant-metastasis-free rate was similar for the bevacizumab and observations arms: 59% vs 54% (HR 0.91; 95% CI, 0.77-1.07; P =.24).

Read more of Oncology Nurse Advisor's coverage of the 2017 American Society of Clinical Oncology Annual Meeting by visiting the conference page.

Reference

Corrie P, Marshall A, Lorigan P, et al. Adjuvant bevacizumab as treatment for melanoma patients at high risk of recurrence: final results for the AVAST-M Trial. Oral presentation at: 2017 American Society of Clinical Oncology Annual Meeting; June 2-6, 2017; Chicago, IL.

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs